GPBAR1 and Obesity: Taken together, the data of Figure 2A–F suggest that INT-767 reverses HFD-induced obesity and liver dysfunction via activation of both FXR and TGR5, whereas the reversal of hypercholesterolemia or liver steatosis by INT-767 is dependent on activation of FXR.